ticlopidine has been researched along with Hyperemia in 3 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 7.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 3.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahmus, JD | 1 |
| Bruning, RS | 1 |
| Kenney, WL | 1 |
| Alexander, LM | 1 |
| Salimi, S | 1 |
| Lewis, JP | 1 |
| Yerges-Armstrong, LM | 1 |
| Mitchell, BD | 1 |
| Saeed, F | 1 |
| O'Connell, JR | 1 |
| Perry, JA | 1 |
| Ryan, KA | 1 |
| Shuldiner, AR | 1 |
| Parsa, A | 1 |
| Hamilos, M | 1 |
| Muller, O | 1 |
| Ntalianis, A | 1 |
| Trana, C | 1 |
| Bartunek, J | 1 |
| Sarno, G | 1 |
| Mangiacapra, F | 1 |
| Dierickx, K | 1 |
| Meeus, P | 1 |
| Cuisset, T | 1 |
| De Bruyne, B | 1 |
| Wijns, W | 1 |
| Barbato, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)[NCT00799396] | Phase 4 | 682 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation. (NCT00799396)
Timeframe: Measured at baseline, and after clopidogrel treatment
| Intervention | percentage of maximum aggregation change (Mean) | |
|---|---|---|
| PRP ADP 20 | PRP Collagen 5 | |
| Overall Study | 38.51 | 14.06 |
Baseline minus post clopidogrel/post-aspirin platelet rich plasma (PRP) maximum aggregation (NCT00799396)
Timeframe: Measured at baseline, and after clopidogrel plus aspirin treatment
| Intervention | percentage of max aggregation change (Mean) | |
|---|---|---|
| PRP ADP 20 | PRP Collagen 5 | |
| Overall Study | 41.21 | 56.64 |
2 trials available for ticlopidine and Hyperemia
| Article | Year |
|---|---|
Oral clopidogrel improves cutaneous microvascular function through EDHF-dependent mechanisms in middle-aged humans.
Topics: Administration, Oral; Analysis of Variance; Aspirin; Biological Factors; Blood Flow Velocity; Clopid | 2013 |
Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation.
Topics: Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Endothelium, Vascular; Female; Genotype; Healthy | 2016 |
1 other study available for ticlopidine and Hyperemia
| Article | Year |
|---|---|
Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; | 2011 |